Mucosal human immunodeficiency virus vaccine late pre-clinical evaluation

In this project we propose to extend our existing non human primate (NHP) vaccines, which are progressing strongly through preclinical trialswith financial support from ACH2 and NHMRC, to encompass an HIV-1 envelope glycoprotein (Env) booster. These vaccines already providegood immunity in primates by generating exceptionally high quality T cells to Gag and Pol (a key target for HIV immunity). By adding an Envbooster we will create a triple-action primate vaccine with enhanced clinical potential resulting from the combination of high-quality Gag/PolspecificT cells and antibody responses to not only Gag but Env.